The Supply Chain Attack on a Critical Component
You are the security architect for a company that manufactures IoT medical devices. Your devices use a third-party software library (LibX) for encryption. You have just learned that LibX has a critical vulnerability (CVE-2025-1234) that allows remote code execution. The vulnerability was introduced in version 2.0, and you are using version 2.3. The vendor has released a patch in version 2.4, but it requires a firmware update that must be pushed to 50,000 devices in the field. Some devices are in hospitals, some in homes. The update process requires user consent for home devices. Your company is subject to FDA regulations and GDPR. You have 30 days to respond to the vulnerability per your internal policy. The vendor has not provided a detailed root cause analysis. Your CEO asks if you should wait for more information or act immediately.
1. What are the regulatory and security considerations for responding to this vulnerability, and what immediate actions should you take?
Read the worked answer
Under FDA regulations, you have a duty to monitor and address cybersecurity vulnerabilities in marketed devices. You must assess the risk and take corrective action, including customer communication. Under GDPR, if the vulnerability could lead to a personal data breach, you must consider notification obligations, but here the risk is to device functionality and potentially patient safety. Immediate actions: 1) Conduct a risk assessment: CVSS score, exploitability, potential impact on device safety and data. 2) Develop a remediation plan: patch development, testing, and deployment. 3) Notify the FDA if the vulnerability could cause serious harm or death (per 21 CFR Part 806 for recalls, but this may be a cybersecurity vulnerability requiring notification under FDA guidance). 4) Communicate with customers (hospitals and home users) about the risk and mitigation. For home devices, provide clear instructions and obtain consent for update. 5) Implement compensating controls (e.g., network segmentation, monitoring) until patch is deployed. 6) Do not wait for root cause analysis; act on the patch. The vendor's lack of RCA is a concern, but you can proceed with patch while requesting RCA. 7) Update your SBOM and vulnerability management records. 8) Consider whether to continue using LibX and evaluate alternatives. Document all decisions. The 30-day policy is a guideline; given criticality, aim to patch within 30 days, but prioritize based on risk.
2. How would you manage the update rollout to 50,000 devices, balancing speed and safety, and what would you do if some hospitals refuse the update?
Read the worked answer
Prioritize rollout based on risk: first update devices in critical care settings (hospitals) where exploitation could cause immediate harm, then home devices. Use a phased approach: pilot on a small set of devices (e.g., 100) to verify patch stability, then expand. For hospitals, coordinate with their IT and biomedical teams, provide a detailed security advisory, and offer assistance. For home devices, use automatic updates where possible, but obtain consent via app notification or email. If hospitals refuse, document their decision and provide compensating controls: network segmentation, intrusion detection, and monitoring. Escalate to your legal team to assess contractual obligations. You may need to notify FDA if refusal leads to significant risk. Consider offering alternative mitigations (e.g., disabling the vulnerable feature). Track update compliance rates and follow up with non-compliant customers. If a hospital refuses due to operational concerns, work with them to schedule the update during downtime. Ultimately, you cannot force an update, but you must ensure they understand the risk. Document all communications and decisions for regulatory purposes.